Your browser doesn't support javascript.
loading
Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers.
Page, Raymond; Patil, Darshana; Akolkar, Dadasaheb; Murthy, Sudha S; Bendale, Kiran; Patil, Revati; Fulmali, Pradeep; Fulmali, Pooja; Adhav, Archana; Puranik, Sneha; Apurwa, Sachin; Datta, Vineet; Bose, Chirantan; Schuster, Stefan; John, Jinumary; Srinivasan, Ajay; Datar, Rajan.
Afiliación
  • Page R; Department of Biochemical Engineering, Worcester Polytechnic Institute, Worcester, Massachusetts, United States of America.
  • Patil D; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Akolkar D; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Murthy SS; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Bendale K; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Patil R; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Fulmali P; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Fulmali P; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Adhav A; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Puranik S; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Apurwa S; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Datta V; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Bose C; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Schuster S; Datar Cancer Genetics Europe GmbH, Eckersdorf, Bavaria, Germany.
  • John J; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Srinivasan A; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
  • Datar R; Department of Research and Innovation, Datar Cancer Genetics, Nasik, Maharashtra, India.
PLoS One ; 17(6): e0270139, 2022.
Article en En | MEDLINE | ID: mdl-35714131
Biomarker directed selection of targeted anti-neoplastic agents such as immune checkpoint inhibitors, small molecule inhibitors and monoclonal antibodies form an important aspect of cancer treatment. Immunohistochemistry (IHC) analysis of the tumor tissue is the method of choice to evaluate the presence of these biomarkers. However, a significant barrier to biomarker testing on tissue is the availability of an adequate amount of tissue and need for repetitive sampling due to tumor evolution. Also, tumor tissue testing is not immune to inter- and intra-tumor heterogeneity. We describe the analytical and clinical validation of a Circulating Tumor Cell (CTC) assay to accurately assess the presence of PD-L1 22C3 and PD-L1 28.8, ER, PR and HER2, from patients with solid tumors to guide the choice of suitable targeted therapies. Analytically, the test has high sensitivity, specificity, linearity and precision. Based on a blinded case control study, the clinical sensitivity and specificity for PD-L1 (22C3 and 28.8) was determined to be 90% and 100% respectively. The clinical sensitivity and specificity was 83% and 89% for ER; 80% and 94% for PR; 63% and 89% for HER2 (by ICC); and 100% and 92% for HER2 (by FISH), respectively. The performance characteristics of the test support its suitability and adaptability for routine clinical use.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Células Neoplásicas Circulantes Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Células Neoplásicas Circulantes Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos